StreetInsider.com News Articles

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

Wed, 02 Sep 2026 08:30:00 -0400

MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.

Mr. Bagai and Mr. Voll will discuss RenovoRx’s record second quarter revenue, driven by

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

Wed, 02 Sep 2026 08:30:00 -0400

Mr. Bagai and Mr. Voll will discuss RenovoRx’s record second quarter revenue, driven by

RenovoRx publishes PK/PD data from pancreatic cancer drug trial

Tue, 25 Aug 2026 08:31:35 -0400

RenovoRx, Inc. (NASDAQ: RNXT) announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.

The sub-study compared intra-arterial gemcitabine delivered via the company's TAMP (Trans-Arterial Micro-Perfusion) platform using its RenovoCath device against standard intravenous gemcitabine in 16 patients with locally advanced pancreatic cancer (LAPC) across six clinical sites. Eleven patients received intra-arterial gemcitabine and five received intravenous gemcitabine.

Key findings from the study include a targeted extraction ratio of 0.511, indicating approximately 51% of the intra-arterially delivered gemcitabine was extracted at the tumor site before entering

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

RenovoRx regains Nasdaq minimum bid price compliance

Fri, 21 Aug 2026 08:30:24 -0400

RenovoRx, Inc. (NASDAQ: RNXT) announced it has received written notification from Nasdaq confirming the company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Nasdaq's Listing Qualifications Staff notified RenovoRx on Aug. 20, 2026, that the closing bid price of its common stock was at $1.00 per share or greater for 10 consecutive business days from Aug. 6 through Aug. 19, 2026. The company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq confirmed the matter is closed. RenovoRx had originally received a deficiency notice from Nasdaq on Dec. 31, 2025.

The notification

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Fri, 21 Aug 2026 08:30:00 -0400

MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

On August 20, 2026, the Nasdaq Listing Qualifications Staff notified RenovoRx in writing that the closing bid price of its common stock was at $1.00

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Fri, 21 Aug 2026 08:30:00 -0400

On August 20, 2026, the Nasdaq Listing Qualifications Staff notified RenovoRx in writing that the closing bid price of its common stock was at $1.00

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Fri, 21 Aug 2026 08:30:00 -0400

On August 20, 2026, the Nasdaq Listing Qualifications Staff notified RenovoRx in writing that the closing bid price of its common stock was at $1.00

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Fri, 21 Aug 2026 08:30:00 -0400

On August 20, 2026, the Nasdaq Listing Qualifications Staff notified RenovoRx in writing that the closing bid price of its common stock was at $1.00

Form 8-K RenovoRx, Inc. For: Aug 20

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956181.html

Form 8-K RenovoRx, Inc. For: Aug 20

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956181.html

RenovoRx receives USPTO notice of allowance for RenovoCath patent

Thu, 20 Aug 2026 08:30:47 -0400

RenovoRx, Inc. (NASDAQ: RNXT) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering its RenovoCath dual-occlusion catheter system, used for targeted drug delivery in cancer treatment.

The allowed application, U.S. Application No. 18/184,620, is titled "Methods and Apparatuses for Delivery of Therapeutic Materials for the Treatment of Cancer." The claims cover RenovoCath's catheter system, which includes a primary catheter, multiple ports, and expandable occlusion balloons designed to seal a segment of a blood vessel and create a controlled treatment zone. A secondary catheter can be advanced through the primary catheter into

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

Thu, 20 Aug 2026 08:30:00 -0400

As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath

MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application (U.S. Application No. 18/184,620) titled “Methods and Apparatuses for Delivery

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

Thu, 20 Aug 2026 08:30:00 -0400

As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath
MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application (U.S. Application No. 18/184,620) titled “Methods and Apparatuses for Delivery

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

Thu, 20 Aug 2026 08:30:00 -0400

As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath
MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application (U.S. Application No. 18/184,620) titled “Methods and Apparatuses for Delivery

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

Thu, 20 Aug 2026 08:30:00 -0400

As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath
MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application (U.S. Application No. 18/184,620) titled “Methods and Apparatuses for Delivery

Form 10-Q RenovoRx, Inc. For: Jun 30

Thu, 13 Aug 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260813/26921153.html

Form 10-Q RenovoRx, Inc. For: Jun 30

Thu, 13 Aug 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260813/26921153.html

Form 8-K/A RenovoRx, Inc. For: Aug 12

Thu, 13 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260813/26920917.html

Form 8-K/A RenovoRx, Inc. For: Aug 12

Thu, 13 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260813/26920917.html

RenovoRx, Inc. (RNXT) Tops Q2 EPS by 2c

Wed, 12 Aug 2026 17:13:05 -0400

RenovoRx, Inc. (NASDAQ: RNXT) reported Q2 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).
For earnings history and earnings-related data on RenovoRx, Inc. (RNXT) click here.

Form 8-K RenovoRx, Inc. For: Aug 12

Wed, 12 Aug 2026 16:17:00 -0400
si-local-file:///var/storage/secattach/20260812/26913125.html